From differences in means between cases and controls to risk stratification: a business plan for biomarker development.
about
DNA methylation biomarkers: cancer and beyondPrecursors in cancer epidemiology: aligning definition and functionIdentification of Circulating Tumor DNA for the Early Detection of Small-cell Lung CancerEurogin 2016 Roadmap: how HPV knowledge is changing screening practice.Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china.A statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study.Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.Screening: A risk-based framework to decide who benefits from screeningDiscovery and validation of methylation markers for endometrial cancer.Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.Triage of HPV-positive women in cervical cancer screening.HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancerMultiple biopsies and detection of cervical cancer precursors at colposcopy.Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention.Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer DiagnosisInvited Commentary: Clinical Utility of Prediction Models for Rare Outcomes--The Example of Pancreatic Cancer.Detecting clinically meaningful biomarkers with repeated measurements: An illustration with electronic health records.Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.Risk assessment to guide cervical screening strategies in a large Chinese population.From clinical epidemiology to practice recommendations: Knowledge gaps and uncertainty in the management of anal precancers.A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations.Large ovarian cancer screening trial shows modest mortality reduction, but does not justify population-based ovarian cancer screening.Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions.Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women
P2860
Q26996421-6C39DE41-A70D-4656-95FE-EFB50E81135FQ28387064-A6D7DA45-2FF6-4C07-92CE-ECF2E601CD87Q28390093-6B3EB5A5-599E-49EC-8392-90893D3ADCF1Q30239987-A6446987-8578-47EA-8CE5-1F65DED04D63Q30278596-D5D6FB18-5E2C-4F82-9E49-2863F35694CDQ30977795-D5ACA344-C3C0-4C48-B69F-FAD1F60C9929Q33847952-184C23AD-EF7F-4E9A-BDD3-DB8D1D456C71Q33894116-696346C7-431D-4859-BEDA-1280F0B6B4CBQ34020931-95F10E20-545B-4A26-8917-2687916946D9Q34058759-D97A60D3-C6E5-4EF6-BABC-6745E1740EBEQ34344762-0FB115BB-4BE1-4A55-B0BE-4B46CA87500FQ34675069-4548C1CE-F4BE-478C-9F98-6F6C065AAA0AQ34716608-FE75CA81-A58D-452F-A54A-6452456F2C25Q35112414-0E7D114D-C1D1-44E9-A235-8D1194CDB4B4Q35775703-083A3C28-97F9-473E-92D3-4A6353EF3B07Q35775708-09DCA72A-9077-4701-99DC-6591C19E2A19Q35778739-A5C1FA3A-C348-4ED7-838C-DB8A5C5493B5Q40186128-3D210466-6096-4678-8982-CC52163559C9Q40821522-00F94DDD-2343-4A25-A266-E9F497244ACBQ48287472-324B9E4A-62A0-4EA1-A381-605BE6CC82D6Q49904079-B7B1C743-D63B-433A-B94B-FB99CBA4BB95Q51621475-1BCEC071-5389-43BE-91EC-0982F3B4C3C8Q52725707-51C7FAF5-0D25-4F53-8122-3F29F69A4B35Q56028141-42775107-34F4-4F25-9530-181943236CC0
P2860
From differences in means between cases and controls to risk stratification: a business plan for biomarker development.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
From differences in means betw ...... lan for biomarker development.
@ast
From differences in means betw ...... lan for biomarker development.
@en
type
label
From differences in means betw ...... lan for biomarker development.
@ast
From differences in means betw ...... lan for biomarker development.
@en
prefLabel
From differences in means betw ...... lan for biomarker development.
@ast
From differences in means betw ...... lan for biomarker development.
@en
P2860
P1433
P1476
From differences in means betw ...... lan for biomarker development.
@en
P2860
P304
P356
10.1158/2159-8290.CD-12-0196
P577
2013-01-08T00:00:00Z